Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7076731 | 0.85 | RAPGEF3 (0.43) | RAPGEF3PPARGKAT6ALTA4HHCRTR2 | |
| SCHEMBL7077441 | 0.83 | AGTR1 (0.33) | AGTR1AGTR2LTA4H | |
| SCHEMBL7080333 | 0.82 | GRM2 (0.41) | — | |
| SCHEMBL7080646 | 0.75 | ITGAV (0.33) | AGTR1AGTR2LTA4H | |
| SCHEMBL7080257 | 0.74 | PTGS2 (0.38) | POLB | |
| SCHEMBL7083339 | 0.71 | CAPN1 (0.46) | PPARG | |
| SCHEMBL7078520 | 0.67 | ALDH1A1 (0.53) | POLB | |
| SCHEMBL7080300 | 0.65 | ALDH1A1 (0.48) | KAT6A | |
| SCHEMBL7076729 | 0.65 | MTNR1B (0.45) | RAPGEF3KAT6A | |
| SCHEMBL7083951 | 0.65 | SMN1; SMN2 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | AJINOMOTO CO. INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-6555584-B1 | Acetyl-coa carboxylase inhibitors | AJINOMOTO CO., INC. (JP) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | ACSS2, ACACA, FASN | RAPGEF3 4803/4885AGTR1 845/4885AGTR2 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.